What's breaking now, across thousands of outlets.
Payments-based revenue rose 18% as Shift4 expanded across key verticals.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Phase 3 LUCIDITY results keep avexitide on track toward a 2027 launch.
Federal deals and AI demand lifted results above guidance.
Oncology and AI-driven efficiencies anchor the quarter's stronger profit picture.
Shift4 beat earnings soundly. Then the selling began.
Legend integration and NFL betting strength drove a beat on guidance.